Covered recipient · General Payments record
SUJITH RAO KALMADI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$236,880.70
390 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $115,344.25 | 55 |
| Consulting Fee | $84,205.83 | 35 |
| Honoraria | $23,176.00 | 17 |
| Travel and Lodging | $7,992.11 | 35 |
| Food and Beverage | $6,029.77 | 244 |
| Education | $132.74 | 4 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 7 of 8; records 301–350 of 390 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SUJITH RAO KALMADI
NPI 1508973447 · CMS profile ID 22736
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
CHANDLER, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 7 of 8; records 301–350 of 390 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=7#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SUJITH RAO KALMADI, NPI 1508973447, CMS profile ID 22736. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 8; records 301–350 of 390 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SUJITH RAO KALMADI, NPI 1508973447, CMS profile ID 22736. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 8; records 301–350 of 390 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SUJITH RAO KALMADI, NPI 1508973447, CMS profile ID 22736, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 8; records 301–350 of 390 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=7#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
390 matching records · $236,880.70 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 301–350 of 390.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $1,890.00 | 04/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845603359 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $16.56 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781011555 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.32 | 04/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834348881 | CMS |
| Taiho Oncology, Inc. | $1,650.00 | 04/23/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843384057 | CMS |
| AstraZeneca Pharmaceuticals LP | $8.96 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834324261 | CMS |
| Kite Pharma, Inc. | $14.46 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844415925 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.54 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763474954 | CMS |
| Incyte Corporation | $695.95 | 04/21/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835551315 | CMS |
| Incyte Corporation | $123.54 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835551317 | CMS |
| Kite Pharma, Inc. | $0.40 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844415921 | CMS |
| Amgen Inc. | $15.10 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826540405 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,370.00 | 04/19/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834340027 | CMS |
| Novartis Pharmaceuticals Corporation | $16.48 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812739411 | CMS |
| AngioDynamics, Inc. | $2,000.00 | 04/16/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793078061 | CMS |
| Karyopharm Therapeutics Inc. | $2,250.00 | 04/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845789063 | CMS |
| Incyte Corporation | $19.03 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835551285 | CMS |
| Daiichi Sankyo Inc. | $235.00 | 04/08/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836279959 | CMS |
| Incyte Corporation | $2,910.00 | 04/06/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835551281 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 04/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834343269 | CMS |
| Daiichi Sankyo Inc. | $19.75 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836281273 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.65 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783580599 | CMS |
| Celgene Corporation | $15.60 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783712517 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.57 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834340131 | CMS |
| Incyte Corporation | $60.48 | 04/01/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835551277 | CMS |
| JAZZ PHARMACEUTICALS INC. | $23.78 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845580683 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.90 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783580591 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 03/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834334233 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.38 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783580593 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.64 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783580595 | CMS |
| Incyte Corporation | $112.80 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835551273 | CMS |
| Celgene Corporation | $19.04 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783712515 | CMS |
| Merck Sharp & Dohme Corporation | $14.81 | 03/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848507415 | CMS |
| Genentech USA, Inc. | $12.41 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835981661 | CMS |
| Janssen Biotech, Inc. | $3.96 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788333753 | CMS |
| Janssen Biotech, Inc. | $6.53 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788333755 | CMS |
| Astellas Pharma US Inc | $39.02 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821388129 | CMS |
| Daiichi Sankyo Inc. | $1,527.50 | 03/23/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836240417 | CMS |
| Daiichi Sankyo Inc. | $1,527.50 | 03/23/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836240733 | CMS |
| Gilead Sciences, Inc. | $20.79 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848218279 | CMS |
| Celgene Corporation | $14.94 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783712511 | CMS |
| Merck Sharp & Dohme Corporation | $16.64 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848318595 | CMS |
| Novartis Pharmaceuticals Corporation | $14.60 | 03/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812739407 | CMS |
| Novocure Inc. | $2,250.00 | 03/19/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 823639591 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5.08 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783580589 | CMS |
| Myovant Sciences Inc. | $18.59 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834961635 | CMS |
| GENZYME CORPORATION | $11.52 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843531297 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.21 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783580581 | CMS |
| Amgen Inc. | $17.43 | 03/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826440729 | CMS |
| Celgene Corporation | $18.67 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783712513 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.64 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783580583 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,284,149.49 | 49 |
| PY2024 | Recipient | $940.00 | 1 |
| PY2024 | Principal investigator | $531,188.02 | 33 |
| PY2023 | Principal investigator | $150,515.07 | 37 |
| PY2022 | Principal investigator | $428,756.22 | 82 |
| PY2021 | Recipient | $1,270.00 | 2 |
| PY2021 | Principal investigator | $346,769.79 | 55 |
| PY2020 | Principal investigator | $249,314.14 | 41 |
| PY2019 | Principal investigator | $311,146.25 | 45 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
49 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,413.00 | 12/24/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387147 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $21,352.00 | 12/11/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387165 |
| Principal investigator 1 | PFIZER INC. | $820.00 | 12/11/2025 | Non-covered Recipient Entity ADMINISTRATORS OF THE TULANE EDUCAT | A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RECURRENT OR METASTATIC CERVICAL CANCER | No dispute reported | 06/30/2026 | 1228702328 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $128.00 | 12/04/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387149 |
| Principal investigator 1 | PFIZER INC. | $2,542.80 | 10/28/2025 | Non-covered Recipient Entity Ironwood Physicians PC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228743533 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $21,855.72 | 10/23/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369846 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,401.00 | 10/23/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 10/09/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $946.30 | 10/09/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14,480.99 | 10/09/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369856 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $564.00 | 08/27/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $23,390.00 | 08/27/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369840 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,090.00 | 08/27/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369852 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $390.00 | 08/13/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,284.25 | 08/06/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369838 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $18,103.45 | 08/06/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369854 |
| Principal investigator 1 | PFIZER INC. | $1,017.90 | 07/28/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228787761 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14,784.00 | 07/24/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369848 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,576.00 | 07/24/2025 | Non-covered Recipient Entity Ironwood Physicians, Pc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369850 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,683.09 | 06/24/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1223387137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 06/19/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $9,964.00 | 06/13/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387145 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 06/05/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387161 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $175.00 | 06/05/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387163 |
| Principal investigator 1 | PFIZER INC. | $1,017.90 | 06/02/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228778171 |
| Principal investigator 1 | PFIZER INC. | $16,949.25 | 05/05/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228724712 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15,311.10 | 04/24/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387159 |
| Principal investigator 1 | PFIZER INC. | $810.00 | 04/21/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228779541 |
| Principal investigator 1 | PFIZER INC. | $4,896.45 | 04/14/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228781351 |
| Principal investigator 1 | PFIZER INC. | $26,954.10 | 04/14/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228794182 |
| Principal investigator 1 | PFIZER INC. | $19,014.75 | 04/14/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228795098 |
| Principal investigator 1 | PFIZER INC. | $3,029.40 | 04/14/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228795340 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $400.00 | 04/10/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387141 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 04/05/2025 | Non-covered Recipient Entity Ironwood Physicians PC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228796470 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34,200.00 | 04/04/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1223387135 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $9,050.00 | 04/04/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387157 |
| Principal investigator 1 | PFIZER INC. | $5,316.30 | 03/31/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228779095 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,749.00 | 03/06/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 03/06/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387155 |
| Principal investigator 1 | PFIZER INC. | $405.00 | 02/25/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228789633 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,262.00 | 02/20/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387129 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $24,048.00 | 02/13/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387131 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $9,009.30 | 02/13/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387133 |
| Principal investigator 1 | Genentech, Inc. | $3,150.00 | 02/04/2025 | Non-covered Recipient Entity IRONWOOD CANCER & RESEARCH CENTERS IRONWOOD PHYSICIANS PC | Phase III Ipatasertib plus abiraterone in mCRPC 1st Line | No dispute reported | 06/30/2026 | 1211617634 |
| Principal investigator 1 | PFIZER INC. | $1,957.50 | 02/03/2025 | Non-covered Recipient Entity IRONWOOD PHYSICIANS PC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228719775 |
| Principal investigator 1 | AstraZeneca UK Limited | $750,532.90 | 01/31/2025 | Non-covered Recipient Entity IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185540243 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11,134.48 | 01/16/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387139 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14,151.20 | 01/16/2025 | Non-covered Recipient Entity Urologic Health Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387151 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $147,939.36 | 01/03/2025 | Non-covered Recipient Entity IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I | This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III | No dispute reported | 06/30/2026 | 1185540245 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 2 |
| PY2024 | Value of interest | $7,150.00 | 2 |
| PY2023 | Amount invested | $7,000.00 | 2 |
| PY2023 | Value of interest | $7,650.00 | 2 |
| PY2022 | Amount invested | $650.00 | 1 |
| PY2022 | Value of interest | $650.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
5 records · PY2022–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | Cornerstone Specialty Network LLC | $0.00 | $650.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1126328607 |
| PY2024 | Cornerstone Specialty Network LLC | $0.00 | $6,500.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1126328609 |
| PY2023 | Cornerstone Specialty Network LLC | $0.00 | $650.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1022148873 |
| PY2023 | Cornerstone Specialty Network LLC | $7,000.00 | $7,000.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1022148879 |
| PY2022 | Cornerstone Specialty Network LLC | $650.00 | $650.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 923382953 |